Avacta Group PLC (AVCT)

London
118.40
-5.50(-4.51%)
  • Volume:
    594,202
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    118.40 - 118.40

AVCT Overview

Prev. Close
122
Day's Range
118.4-118.4
Revenue
4.15M
Open
120.5
52 wk Range
88.5-291.8
EPS
-0.09
Volume
594,202
Market Cap
296.45M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
1,714,736
P/E Ratio
-
Beta
1.77
1-Year Change
-32.73%
Shares Outstanding
250,378,346
Next Earnings Date
19 Apr 2022
What is your sentiment on Avacta Group PLC?
or
Market is currently closed. Voting is open during market hours.

Avacta Group PLC News

Avacta Group PLC Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuySellSellStrong SellSell
Technical IndicatorsStrong BuyBuyStrong SellBuyStrong Sell
SummaryStrong BuyNeutralStrong SellNeutralStrong Sell

Avacta Group PLC Company Profile

Avacta Group PLC Company Profile

Employees
123

Avacta Group plc is a biotechnology company. Avacta's focus is on its proprietary Affimer technology which is an engineered alternative to antibodies that has application in Life Sciences for diagnostics, therapeutics and general research and development. Affimer technology has been designed to address performance limitations of antibodies. Affimer technology is based on a small protein that can be generated to bind with specificity and affinity to a range of targets to enable diagnostics, research assays and therapeutics. Avacta has a pre-clinical therapeutic development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.

Read More
  • Or even ********
    2
    • ETF!
      0
      • UK demand alone for 'accurate' & easy to perform rapid lateral flow tests is apparently running at c. 1.8m units/day. Thus hypothetically at say £5 each, that's a revenue run-rate (whilst schools are open) of £9m/day, or >£200m/month. Not bad news for the likes of Avacta, Omega Diagnostics & Abingdon health, along with PCR testing firms such as Novacyt & SourceBio Internationa, who should also benefit from extra 'knock-on' confirmatory volume having to be performed by their mobile/fixed labs.
        2
        • All coming speedily to fruition, with regard to the covid test’s. The cash gsnerated will fund th Ed cancer side. This will bs the major bread winner. Of course after a future Nasdaq quoute, this will most likely lead to a take out by sons big pharma. Buy now, in the next 3 weeks this share will be much higher, imo
          0
          • why such a bounce? now back to where it was 2 days ago
            0
            • FOMO Friday
              0
          • am l the only one thinks once the manufacturing details are released this will go to at least £4? With the LFT printing money every second for the next year at least, a buyback, special dividend or takeover has to be on the cards, likely the later given the start of that ava6000 cancer therapy trials.
            2
            • buy and hold...as the new spread re the tests it should boost price further.
              1
            • This will be sales of LFT test kits in the UK, then Europe and even world wide could follow, so it could go much higher, 👍
              0
          • Avacta have the best rapid antigen test going. Only one way from here...
            3
            • SP finally going down. CEO has a nice house from the sale proceeds
              5
              • CEO sold some of his holding. So? Guess he could have sold out completely if he had no faith.
                1
            • https://www.gov.uk/government/news/government-invests-in-uk-developed-antibody-tests-from-uk-rapid-test-consortium
              0
              • 6th October old news??
                0
            • Take a look at ODX, Omega Diagnostics Limited. Part of the consortium for UK-RTC. Abingdon have been awarded a 75m conteact today and 25% of it will go to Omega. The other 2 companies in the consortium are not listed. You can imagine the potentional. So far 717% rise. You can do your research to verify the above, but you’ll not be dissapointed.
              8
              • too many parties involved . of the £75m divide by 2 to get costs out of the way. then divide by 4. profit =£9m.odx looks fairly valued here. if there were not any other parties involved it would be an easy buy.
                0
            • There is going to be a huge demand for test kits during this winter
              0
              • yes but UK government has chosen a different company
                0
              • Yep, they have. Take a look at ODX, Omega Diagnostics Limited. Part of the consortium for UK-RTC. Abingdon have been awarded a 75m conteact today and 25% of it will go to Omega. The other 2 companies in the consortium are not listed. You can imagine the potentional. So far 717% rise. You can do your research to verify the above, but you’ll not be dissapointed.
                0
              • Pro Fessorwhich company are you reffering to? Abingdon?
                0
            • Anyone know the reason for the sudden drop?
              1
              • Future FTSE 100 company written all over it.
                3
                • solid company with an amazing future ahead CEO is on the ball and has a good buisness mind,can see avacta becoming a massive company in 5-10 years
                  3
                  • I can see this stock going for £5 a share down the line.
                    2
                    • Read Myles McNulty’s 24/6 uodate re valuation..intresring read.
                      1
                    • I think this stock will do very well, it has lots of day traders so that is making it move up and down, but think this has 250 plus even by end of year. company is working hard and many bits of news can follow.
                      0
                  • what's peoples opinions on this stock? I bought them at 125
                    2
                    • looks like a good entry point?
                      0
                      • Just people flitting from one covid stock to another, this one to hold for a while.. it will go up and down but in the end this will be there when the rest fall away. It's not a one trick pony.
                        0
                        • Not sure with this now, looks like it’s stalled. Profit taking maybe?
                          5
                          • Connifer investment and profile of their business tells you everything, only invested in £bn buisnesses amd ... a small Mcap on aim... they are not here for £30m...
                            0
                        • To update, been looking more into this. With ongoing projects alone it is worth almost 666mil. Wow. The pre|CISION for cancer has the “potential” to make 1.2bil.
                          1
                          • Kalpit..Avacta have many other options and partners without the Covid drama... With what they have they could end up a multi billion pound company.In a year or two it could have an SP of £5 to £10
                            0
                            • Company value around 350mil. Mk cap now bit over.
                              1
                              • i recently bought this one at around 145ish and seems like a good one so far - is there anyone who has been here long enough can help me understand if this company has future past COVID?
                                0
                                • Forgot to mention - many thanks in advance
                                  0
                              • Its going up nicely
                                0
                                • lovely RNS today. Just thinking about AVCT. I think the reason why we had so many sellers today is because of the recent good rise. A lot of people would feel justified in taking some out, and that combined with probably a bit of panic selling on the drop, caused the exceptional waves of selling. That's all I can think of.
                                  1
                                  Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                  Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.